61
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

, , , , , , , & show all
Pages 163-172 | Published online: 27 Feb 2017

Figures & data

Table 3 Annual transition probabilities

Table 1 Baseline characteristics of patient population

Table 2 SVR values applied in the model

Table 4 Utilities and costs used in the model

Table 5 Discounted base case results for treatment-experienced patients (F3/F4)

Figure 1 Univariate sensitivity analysis: testing versus no testing.

Abbreviations: DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; NS5A, nonstructural protein 5A; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response; TP, transition probability; Util, utility.
Figure 1 Univariate sensitivity analysis: testing versus no testing.

Figure 2 Probabilistic sensitivity analysis: two-way cost-effectiveness acceptability curve.

Abbreviations: LDV, ledipasvir; NS5A, nonstructural protein 5A; SMV, simeprevir; SOF, sofosbuvir.
Figure 2 Probabilistic sensitivity analysis: two-way cost-effectiveness acceptability curve.

Table 6 Results of scenario analyses